MedTrace Logo

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

NCT00442481 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2007-03-02

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design.

Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.

Conditions

Interventions

DRUG

Escitalopram

PROCEDURE

A baseline overnight polysomnography (oPSG)

Sponsors & Collaborators

  • Lundbeck Israel

    collaborator INDUSTRY

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Jordan Lewinski, Dr. · Sheba Medical Center, Department of psychiatry

  • Mark Weiser, Dr. · Sheba Medical Center, Department of psychiatry

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00442481 on ClinicalTrials.gov